241 related articles for article (PubMed ID: 6160907)
1. Acceleration of allogeneic antitumor immunity with immune RNA in vitro and T-cell suppression by L1210 tumor bearer spleen cells.
Miura T; Maekawa T; Kurashige S; Mitsuhashi S
Cancer Res; 1981 Feb; 41(2):383-98. PubMed ID: 6160907
[TBL] [Abstract][Full Text] [Related]
2. Effector cell stimulation-inhibition of in vitro lymphoma cell DNA synthesis and correlation with in vivo antitumor response.
Gordon WC; Prager MD
Cancer Res; 1977 Feb; 37(2):507-13. PubMed ID: 832275
[TBL] [Abstract][Full Text] [Related]
3. Participation of T-lymphocytes in the curative effect of a novel synthetic polyamine analogue, N,N'-bis[3-(ethylamino)propyl]-1,7-heptanediamine, against L1210 leukemia in vivo.
Bowlin TL; Prakash NJ; Edwards ML; Sjoerdsma A
Cancer Res; 1991 Jan; 51(1):62-6. PubMed ID: 1988107
[TBL] [Abstract][Full Text] [Related]
4. Production of antitumor T-cells in tumor-bearing mice treated with tumor vaccine and 6-mercaptopurine.
Kataoka T; Oh-hashi F
Cancer Res; 1985 Jul; 45(7):2962-6. PubMed ID: 3873988
[TBL] [Abstract][Full Text] [Related]
5. Development of host-dependent high-grade tumor-specific immunity through a novel mechanism triggered by the Lyt-2+ tumor-specific T cell clone (K7L) that induces temporal growth of L1210 leukemia-K7L-variant.
Nagase F; Ueda K; Kawashima K; Jamshedur Rahman SM; Isobe K; Yoshida T; Hasegawa Y; Ando K; Iwamoto T; Nagura E
J Immunol; 1987 Apr; 138(7):2359-65. PubMed ID: 2951438
[TBL] [Abstract][Full Text] [Related]
6. Deficient tumor-specific immunity in old mice: in vivo mediation by suppressor cells, and correction of the defect by interleukin 2 supplementation in vitro but not in vivo.
Bruley-Rosset M; Payelle B
Eur J Immunol; 1987 Mar; 17(3):307-12. PubMed ID: 2952510
[TBL] [Abstract][Full Text] [Related]
7. Tumor growth inhibitory and natural suppressor activities of murine bone marrow cells: a comparative study.
Seledtsov VI; Taraban VY; Seledtsova GV; Samarin DM; Avdeev IV; Senyukov VV; Kozlov VA
Cell Immunol; 1997 Nov; 182(1):12-9. PubMed ID: 9427805
[TBL] [Abstract][Full Text] [Related]
8. Induction of high-grade tumor-specific immunity in a host using a cytotoxic T-lymphocyte clone specific for a stable tumor antigen on murine leukemia L1210.
Rahman SM; Kawashima K; Nakashima I; Nagase F
Cancer Res; 1988 Nov; 48(22):6450-4. PubMed ID: 3263189
[TBL] [Abstract][Full Text] [Related]
9. Pyran (MVE-5) reverses the inhibition of macrophage receptors for cytophilic antibody induced by soluble immune complexes.
Rao VS; Mitchell MS
J Biol Response Mod; 1983; 2(1):67-80. PubMed ID: 6606020
[TBL] [Abstract][Full Text] [Related]
10. Involvement of cytotoxic T-lymphocytes in the antitumor activity of spergualin against L1210 cells.
Umezawa H; Nishikawa K; Shibasaki C; Takahashi K; Nakamura T; Takeuchi T
Cancer Res; 1987 Jun; 47(12):3062-5. PubMed ID: 3495325
[TBL] [Abstract][Full Text] [Related]
11. Analysis of the involvement of cells from donor and recipient mice in adoptive transfer of antitumor immunity.
Lee FH; Currie D; Hwang KM
Cancer Res; 1984 Dec; 44(12 Pt 1):5491-8. PubMed ID: 6208997
[TBL] [Abstract][Full Text] [Related]
12. Significance of suppressor macrophages for immunosurveillance of tumor-bearing mice.
Fujii T; Igarashi T; Kishimoto S
J Natl Cancer Inst; 1987 Mar; 78(3):509-17. PubMed ID: 2950265
[TBL] [Abstract][Full Text] [Related]
13. Curative intravenous adoptive immunotherapy of Meth A murine sarcoma. A histologic and immunohistochemical assessment.
Reichert CM; Rosenstein M; Von Glatz J; Hsu SM; Rosenberg SA
Lab Invest; 1985 Mar; 52(3):304-13. PubMed ID: 3974201
[TBL] [Abstract][Full Text] [Related]
14. In vivo potentiation of concanavalin A-bound L1210 vaccine by antimacrophage agents.
Kataoka T; Oh-hashi F; Sakurai Y; Gomi K
Cancer Res; 1980 Oct; 40(10):3832-8. PubMed ID: 6254642
[TBL] [Abstract][Full Text] [Related]
15. Suppressor cell activity in tumor-bearing mice. I. Dualistic inhibition by suppressor T lymphocytes and macrophages.
Elgert KD; Farrar WL
J Immunol; 1978 Apr; 120(4):1345-53. PubMed ID: 305939
[TBL] [Abstract][Full Text] [Related]
16. Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat gross virus-induced lymphoma.
Bernstein ID
J Immunol; 1977 Jan; 118(1):122-8. PubMed ID: 830744
[TBL] [Abstract][Full Text] [Related]
17. Immunomodulation by various nitrosoureas and its effect on the survival of the murine host bearing a syngeneic tumor.
Nagarkatti M; Toney DM; Nagarkatti PS
Cancer Res; 1989 Dec; 49(23):6587-92. PubMed ID: 2573418
[TBL] [Abstract][Full Text] [Related]
18. Immune mechanisms in leukemia: protective capacity of the major lymphoid cell compartments.
Lukasewycz OA; Duffey PS; Murphy WH
J Immunol; 1976 Apr; 116(4):976-81. PubMed ID: 1082909
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
20. Immune response to murine neuroblastoma: effects of in vitro culture of the tumor. Mitogen and mixed lymphocyte culture responses, interleukin-2 production, suppression and natural killer activity.
Leclercq G; Willems J; Joniau M
J Clin Lab Immunol; 1986 Nov; 21(3):117-23. PubMed ID: 2951523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
